Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
BMRN.OQ - BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. at Wells Fargo Healthcare Conference
Sep 09, 2026 / 07:00PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Launches, right? These are we we have Naglozyme launched in 2005, hit $500 million last year. We have Vimizim launched in 2014, $800 million last year. We have a really durable franchise there, but then we had the addition of Amicus just as we closed this past April, really exciting growth story that I know that we'll likely get into, but we were able to talk a little bit more about the opportunity in our Q2 call. And this is where we're talking about the potential. These are two commercial fast-growing products that we have real potential to expand on, growing to possibly $1.4 billion for Galifold and Fambre and $1.2 billion at peak in the mid-2030s, late 2030s for Pombility and Opfolda in Pompeii. So
Trustpilot
